Delivery Order SPE2DB24D8002-SPE2DB24FJMWM
Award Date
9/4/24
Potential Completion Date
9/5/24
Potential Value
$15K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $9,456.99 to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with an ultimate completion date of October 18, 2024. This award is part of Dakota Drug, Inc.'s Indefinite Delivery Contract (IDC) SPE2DB24D8001 valued at $999,999,999.00, which allows the company to provide a comprehensive range of...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBPZE, was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $16,771.40 Firm Fixed Price Delivery Order contract is for the provision of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a performance period through November 7, 2023. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $8,445.88, is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a performance period ending on March 18, 2025. The contract is a delivery order issued under Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, which has a total potential value of...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product STELARA 90 MG/ML SYRINGE. The contract has a firm fixed price ceiling value of $9,397.47 and a period of performance extending until February 21, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows Dakota Drug, Inc. to provide a...
This federal contract award, identified as SPE2DB24D8001|SPE2DB24FKYYJ, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc. The contract, valued at $10,413.85, is a firm-fixed-price delivery order for the supply of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product. Dakota Drug, Inc. is a self-certified small disadvantaged business operating as a for-profit subchapter S corporation that specializes in providing pharmaceutical products, medical supplies,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of STELARA 90 MG/ML SYRINGEML. The contract has a ceiling value of $9,827.80 and an ultimate completion date of April 9, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense, and this award is part of the company's broader...
This federal contract award, with ID SPE2DB24D8001|SPE2DB25FKZKH, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $9,440.85, is a delivery order for the pharmaceutical product STELARA 90 MG/ML SYRINGE. It is a firm fixed-price contract with a period of performance extending through March 20, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at...
This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKZLG, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract has a ceiling value of $8,114.16 and a period of performance through March 28, 2025. It is a Firm Fixed Price Delivery Order contract,...
This federal contract award, with ID SPE2DB24D8001|SPE2DB24FKYYA, is a delivery order valued at $19,198.65 issued by the Defense Logistics Agency (DLA) to the prime contractor, Dakota Drug, Inc. Dakota Drug, Inc. is a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a period of performance through August 20, 2024. This award is not associated with a...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $20,476.24 firm fixed-price delivery order is for the pharmaceutical product STELARA 90 MG/ML SYRINGEML, with a period of performance through February 27, 2024. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's...